Company intelligence / Profile preview
Seelos Therapeutics, Inc.
New York, New York, United Statesseelostherapeutics.com ↗
- Ownership
- Public · SEEL
- Development stage
- Phase 2
01
Overview
Seelos Therapeutics develops therapies for CNS disorders and rare diseases. Its lead asset, SLS‑002 intranasal racemic ketamine for ASIB in MDD, has completed Phase II studies. Other pipeline assets include trehalose IV infusion for ALS/SCA/Huntington's/Alzheimer's disease at Phase IIb or earlier stages; gene therapies and peptide inhibitors targeting Parkinson's disease are preclinical to early clinical stage. The company faces financial challenges after being delisted from Nasdaq but remains active with ongoing development efforts.[7]
- Therapeutic areas
- Rare DiseasesPsychiatryNeurology
- Modalities
- Small molecules[9]Gene therapy[3][9]Peptide inhibitors[3][6][9]PROTACs[9]AAV-based gene therapy[9]
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Not specifically disclosed; company notes ongoing discussions about potential partnerships focused on mental health initiatives.[10]
04
Financials
- Market cap
- $215K
- Total revenue
- $376K
- Enterprise value
- $10.1M
Beyond the preview
Go deeper on Seelos Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seelos Therapeutics, Inc..